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Abstract: An innovative approach was tested to treat cat allergy in humans by vaccinating cats with
Fel-CuMV (HypoCatTM), a vaccine against the major cat allergen Fel d 1 based on virus-like particles
derived from cucumber mosaic virus (CuMV-VLPs). Upon vaccination, cats develop neutralizing
antibodies against the allergen Fel d 1, which reduces the level of reactive allergen, thus lowering the
symptoms or even preventing allergic reactions in humans. The combined methodological field study
included ten cat-allergic participants who lived together with their cats (n = 13), that were immunized
with Fel-CuMV. The aim was to determine methods for measuring a change in allergic symptoms.
A home-based provocation test (petting time and organ specific symptom score (OSSS)) and a general
weekly (or monthly) symptom score (G(W)SS) were used to assess changes in allergic symptoms. The
petting time until a pre-defined level of allergic symptoms was reached increased already early after
vaccination of the cats and was apparent over the course of the study. In addition, the OSSS after
provocation and G(W)SS recorded a persistent reduction in symptoms over the study period and
could serve for long-term assessment. Hence, the immunization of cats with HypoCatTM (Fel-CuMV)
may have a positive impact on the cat allergy of the owner, and changes could be assessed by the
provocation test as well as G(W)SS.
Keywords: cat allergy; vaccination; Fel d 1; HypoCat™; virus-like particle
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1. Introduction
Cats are among the most popular and common pets worldwide and are a significant source of
indoor allergens [1]. Hence, allergies to cats are widespread, with a prevalence of 10%–30% in the
Western population [2]. A total number of 10 Feline domesticus (Fel d) allergens, that are recognized by
human IgEs, have been identified [3–9]. Fel d 1, an uteroglobin-like protein, is considered to be the
major cat allergen. In fact, 94% of patients allergic to cats have Fel d 1-specific IgE [10]. Fel d 1 belongs
to the family of secretoglobins with homologies to uteroglobin. Its function is unknown but it has been
postulated to play a potential role in skin protection and pelt conditioning or have an involvement in
the transport of steroids, hormones and pheromones [11,12]. Fel d 1 is produced in sebaceous, salivary,
lacrimal, and anal glands and is present in the saliva, tears, skin and fur [13–16]. It is shed from the cat
to the environment through airborne dander and if inhaled by humans may result in sensitization and
induction of cat allergy [17].
The immune response against innocuous cat allergens is characterized as type I and IV
hypersensitivity, involving Th2 cells shaping the environment for production of IgE antibodies by B and
plasma cells and recruitment of additional inflammatory cells [18–20]. Affected patients suffer from mild
symptoms, e.g., sneezing, itchiness of skin and eyes, to severe symptoms ranging from conjunctivitis,
rhinitis to asthma, which, upon direct exposure to cats, can lead to life-threatening conditions. There are
several recommendations for dealing with cat allergy [21]. Allergic people are advised to avoid allergen
exposure by removal of all potential allergen-containing or contaminated objects in the households, e.g.,
pillows, blankets, carpets, rugs. Environmental cleaning and the use of air humidifiers and HEPA filters
can also contribute to the relief of symptoms. Another approach is to remove the cat. However, the
bond between owners and their cats is often so strong that they are more likely to accept the risk to their
health, which they may not even be fully aware of, than give up their pet [22].
Cat allergic subjects usually treat their allergic symptoms with antihistamines and corticosteroids.
Another possibility is allergen specific immunotherapy (AIT), which is the only disease-modifying
option, but carries the risk of inducing serious side effects and may take years. In fact, AIT can require
30–80 injections over a duration of three to five years with a low chance of success. New approaches
explore different routes of administration (e.g., epicutaneous, sublingual, intralymphatic), different
formulations of allergens with adjuvants (e.g., MPL, MCT), the introduction of mutations into the protein
sequence which delete T cell or IgE epitopes, and finally the use of short peptides instead of full-length
allergens [23–31]. The challenge for the development of new therapies is exemplified by the recent failure
of a phase III clinical study testing a peptide-based vaccine to treat cat allergy [32]. Orengo et al. are
developing a monoclonal IgG antibody therapy targeting Fel d 1 in humans that aims to increase the
allergen-specific IgG/IgE ratio and relieve symptoms and showed good clinical impact [33].
An alternative approach to the problem of cat allergy, and one that does not involve separation
of the cat from its owner, is to lower Fel d 1 on the animal itself. One recently described method is
the addition of anti-Fel d 1 IgY harvested from chicken eggs to cat food. A reduction in active Fel d 1
in saliva and fur has been reported but whether this will result in clinically significant reductions in
allergy still needs to be addressed [34,35].
Another approach to lowering allergenic Fel d 1 levels on the cat is active immunization with
the aim of inducing anti-Fel d 1 antibodies in the animal itself. Towards this end, a feline vaccine
targeting Fel d 1 in cats to treat cat allergy in humans is being developed [36]. The vaccine is based on
a recombinantly expressed Fel d 1 protein covalently linked to a virus-like particle (VLP) derived from
the Cucumber mosaic virus (CuMV) [37]. The VLP consists of the CuMV coat protein, without any
viral genetic information, which serves as a carrier and induces, due to its particulate and repetitive
structure, strong and sustained antibody responses, even against self molecules like the Fel d 1 protein
in cats [38,39]. To date, vaccination with Fel-CuMV (HypoCatTM) has been tested in 70 cats and was
well tolerated without short- or long-term (two years) side effects. Furthermore, vaccination induced
strong neutralizing anti-Fel d 1 IgG responses lowering levels of reactive allergen in tear extracts of
study cats tested with human basophils from cat allergic subjects [36].
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In the current manuscript, we report the results of a first field trial with ten cat allergic participants
living together with their cats, and the cats were vaccinated with Fel-CuMV. The aim of this exploratory
methodology study was 1) to determine a suitable method for measuring a change in the allergic
symptoms of the owner and 2) quantify changes in the interactions between the cat and the owner.
These methods may then be used in a larger trials in the future. Three parameters were monitored over
a duration of almost two years. A home-based provocation test determined the petting time, defined
as the time during which the owner was able to interact with the cat until a certain level of symptoms
using a visual analogue scale (VAS score of 5) was reached and their organ-specific symptoms score
(OSSS) after petting their cats. In addition, a general weekly or monthly symptom score (GWSS and
GSS, respectively) assessed overall changes in allergic symptoms in human subjects without interaction
with the cat. The provocation test was assessed as a parameter of the acute allergic reaction, comparable
to a hospital-based provocation test (e.g., nasal or conjunctival test), whereas the G(W)SS served as
readout of chronic symptoms. As observed in previous studies [36], vaccination with Fel-CuMV was
well-tolerated by cats and induced strong serum antibody responses. Changes in symptoms of cat
owners and interaction times with their cats were observed after vaccination of the pets. Thus, both
tests, the provocation test and the G(W)SS, are suitable to detect changes in the symptoms of cat allergic
patients. In particular, the petting time may serve as an early efficacy read-out following vaccination of
the cats, whereas the OSSS and G(W)SS seem to be more appropriate for long-term monitoring.
2. Materials and Methods
2.1. Study Population
The study participants were recruited from March till July 2017 and the study commenced in April
2017. Upon completion in February 2018, an extension study with seven of the study participants was
conducted from May 2018 until April 2019. Males or females aged 18-65 with a history of cat allergy
that were cohabitating with cat(s) were eligible for study inclusion. An understanding of the nature,
meaning and scope of the study and signing of an informed consent were also required. Participants
were also required to test positive for skin prick tests performed with histamine dihdrochloride and
cat allergen extract. In order to confirm the cat allergy to their own cat, participants were also tested
positive by a screening scratch test to fur of their own cat.
Participants were not enrolled if they suffered from immunosuppression or anemias, leukemia or
other hematological diseases. Additional exclusion criteria were: pregnancy, breast feeding or intent to
become pregnant during the course of the study; a positive skin prick test with the negative control; a
known history of anaphylactic reactions to pet allergens; the use of Beta-blockers, neuroleptic drugs
and tricyclic anti-depressants.
Medications like ACE-inhibitors and Beta2-agonists as well as anti-histamines and corticosteroids
could influence the study results and were therefore prohibited within 3 days prior to the application
of allergen extracts or the provocation test.
Main study: Ten cat allergic participants ranging from 21 to 51 years old, including eight women
and two men, were screened and enrolled in the study at the University Hospital Zurich, Switzerland
(Table 1). A total of 13 cats (two participants had two or three cats, respectively) were enrolled in the
animal part of the study.
Extension study: Seven participants, including six women and one man, aged between 22 and 52
years old continued in the extension study. A total of nine cats (one participant had three cats) were
enrolled in the animal part of the study.
2.2. Study Design
The study was a single-center, open-label, non-placebo controlled, combined, methodological
field trial to determine (a) method(s) for measuring cat allergy symptoms in participants that have
immunized their cats with Fel-CuMV.
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Human part: Main study—Screening visits took place at the Clinical Trials Center, University
Hospital Zurich (USZ), CH in collaboration with the Department of Dermatology (USZ). After
the informed consent was given, the participants underwent two tests to confirm their cat allergy.
A skin-prick test was performed using a standard cat allergen and a scratch-test was performed with
fur from the own cat. Home-based provocation tests were performed in study weeks 1–3 before
vaccination of the cat(s), and in weeks 4, 8, 12, 16, 20 and 24 after vaccination of the cat(s). The
provocation test assessed two parameters, the petting time and organ-specific symptoms score (OSSS).
The test was only valid if participants had not taken medication containing anti-histamines less than
3 days before the test, otherwise they had to reschedule the test accordingly. If the rescheduling did not
happen, the test for that timepoint was invalid and not considered in the statistical analysis. Once a
week, the participants filled in a questionnaire retrospectively recording their organ-specific symptoms
of the previous week (i.e., general weekly symptom score GWSS). A close-out phone call at the end of
the study in week 29 was done to follow up on the well-being and health of the study participant.
Extension study - Seven of ten participants of the main study signed the informed consent form
and were enrolled in the extension study. They performed a provocation test before the booster
injection of their cat(s) in study week 1 (or week 54 in the combined schedule of main and extension
study including the intervening time) followed by four additional tests in study weeks 5, 9, 25 and 45
(weeks 58, 62, 78 and 98, respectively). Again, a provocation test was only valid if participants had not
taken medication containing anti-histamines less than 3 days before the test. In the event of a breach,
the procedure was followed as described in the main study. In addition, participants recorded their
general organ-specific symptoms without provocation monthly (i.e., general specific symptoms GSS).
The study finished with a close-out phone call by the clinical study team in study week 45 (week 98,
respectively).
Animal part: All interventions for the cats were performed by study veterinarians at the
“Kleintierpraxis Schwäntenmos” in Zumikon, Zurich, “Ennetseeklinik für Kleintiere AG” in Hünenberg,
Zug and “Tierklinik Aarau West AG” in Aarau, Aargau.
Main study—Thirteen cats were enrolled and received three subcutaneous injections of 100 µg
Fel-CuMV formulated in 1 mL in study weeks 4, 7, and 10. Sera were collected in study weeks 4, 10,
and 27 and analyzed for specific antibody responses.
Extension study—Nine cats received a subcutaneous booster injection of 100µg Fel-CuMV formulated
in 1 mL in week 3 (or week 56 in the combined study schedule). Sera were collected before the boost
(week 56), 6 weeks after the boost (week 62) and at the end of the extension cat study (week 78).
2.3. Ethics Approvals
The protocol, participant information and consent form, as well as other study-specific documents,
were submitted to the Zurich-based properly constituted cantonal ethic committee (KEK) in agreement
with local legal requirements for formal study approval. The decision of the KEK concerning the
conduct of the study had been made in writing to the Sponsor-Investigator before commencement
of this study. The KEK decided the trial could be conducted without its approval, as the law for
human research was judged to be not applicable. From an ethical perspective, the extension study was
considered the same and was conducted without particular approval of the KEK. However, both studies
were conducted in accordance with ICH/GCP Guidelines and registered with CLINICALTRIALS.gov
as NCT03089788.
The Veterinary Offices of the participating cantons Zurich, Zug and Aargau approved the animal
study ZH245/16 (19th March 2016). All cat owners signed informed consent for their cats. All
interventions and examinations performed by the study veterinarians were in accordance to the
Swiss Animal Welfare Ordinance and Animal Welfare Act on Animal Experimentation (2005, TSchG;
2008, TschV). The animal study was designed as an open-label, non-placebo controlled, multi-center,
tolerability and immunogenicity study.
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2.4. Study Objective
The objective of the study was to determine if the methods tested herein (provocation test and
G(W)SS) were suitable to measure changes in allergy symptoms and interaction of the participants
with their cats following immunization with Fel-CuMV (HypoCatTM). The change in symptoms was
assessed at baseline versus week 24 at the end of the main study and over the course of the entire study
(main and extension study). The selected method(s) could be used in future clinical trials.
2.5. Provocation Test
In an earlier study “ZU_Hyposcore-001” (NCT02399579. https://clinicaltrials.gov/ct2/show/results/
NCT02399579) the validity of the provocation test (i.e., HypoScore), a new self-assessed, home-based
score specific for cat allergy, was evaluated in cat-allergic participants without vaccination of their
cats. In the current study, the provocation test was used to observe changes in allergic symptoms
upon vaccination of cats with Fel-CuMV. The test assessed two parameters: the petting time and
organ-specific symptoms score (OSSS). The test was performed by petting the cat in order to measure
the time until the participant reached a defined symptom strength level (self-assessed, 5 on a VAS
ranging from 0–10). If the participant did not reach a symptom level of 5, the petting was stopped
at 45 min. When symptom severity of 5 was not reached but provocation time was <45 min (e.g.,
did not tolerate further petting), for data analysis the time of the last provocation test was carried
forward (LOCF). The petting times were measured at baseline on three occasions (week 1–3) before
immunization of the cat and over the course of main and extension study. After the provocation test,
the participants filled in an OSSS questionnaire on a 4-point scale (0 = no symptoms up to 3 = severe
symptoms) regarding their symptoms of eyes, nose, bronchia, lung and palate. Values of the OSSS
could be between 0 and 30. The baseline of the HypoScore was measured weekly on three occasions
before vaccination of the cats and was compared to the end (week 24) and over the course of the study
(weeks 8, 12, 16, 20 and 24 in the main study and weeks 54, 58, 62, 78 and 98 in the extension study)
after vaccination of the cats in weeks 4, 7, 10 and booster injection in week 56.
2.6. General Weekly or Monthly Specific Symptoms (GWSS or GSS)
Changes in the general organ specific symptoms on a 4-point scale (0 = no symptoms up to 3 =
severe symptoms) of eyes, nose, bronchia, lung, and palate were assessed weekly in the main study
(GWSS) or monthly in the extension study (GSS) before and after vaccination of cats with Fel-CuMV.
The test was performed without provocation (i.e., direct interaction with their cat). Values of the
G(W)SS could be between 0 and 30. The baseline of the general symptoms was determined on three
occasions (week 1–3) before vaccination and on 22 occasions during the main study (week 4–25) and
12 occasions during the extension study (week 54-98) after vaccination of the cats in study weeks 4, 7,
10 and booster injection in week 56.
2.7. Cat Population
The cats which participated in the study were privately owned and included 13 cats of six breeds
including; British Shorthair, European Shorthair, Russian Blue, Ragdoll, Abyssinian, and Egyptian Mau
of both sexes (7 ♀; 6 ♂). The age ranged from 4 to 13 years and body weights of 2.5 to 7.4 kg. Thirteen
animals were enrolled in the main and nine cats in the extension study. Where several cats lived in the
same household, all cats were immunized, but only one cat was designated as the study cat. The cat
owner performed the provocation tests and answered all questionnaires regarding the single study cat.
2.8. Vaccination of Cats
The vaccine Fel-CuMV and the vaccine production was described previously [36]. A vaccine dose
contained 100 µg Fel-CuMV (HypoCatTM) formulated in 1 mL aqueous buffer solution. Subcutaneous
injections were applied in study weeks 4, 7 and 10 (main study) and 56 (extension study). The vaccine
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used in this study was produced by Benchmark Vaccines Limited, UK using a GMP-like production
process. Prior to each vaccination, the cats were thoroughly examined by one of the participating
veterinarians for their general health status, including a routine physical exam with measurement of
the body weight and temperature, checking the site of injection, pulse and breathing rate, abdomen
palpation and general appearance. During the course of the study, the owners regularly checked the
health of their animal. Twenty-four hours after every injection the owners were called by the study
personnel to enquire after the well-being of the cat.
2.9. Antibody Responses in Cats
Blood for serum antibody measurements was collected from the vena jugularis or cephalica using
serum tubes (Sarstedt, Germany). Sampling was done in the study weeks 4, 7, 10, 27, 56, 62, and 78.
After clotting (30 min) and centrifugation (1000 ×g, 5 min) of blood samples, sera were transferred to
labeled polypropylene tubes (Eppendorf tubes, 1.5 mL, Germany) and stored at ≤ −15 ◦C until thawed
for antibody analyses.
A validated ELISA (developed by HypoPet AG) was performed to determine anti-Fel d 1 IgG in
cat sera previously described [36]. ELISA titers are given as the reciprocals of the dilutions needed to
achieve 50% of the optical density of the maximal signal measured at saturation (OD50). The geometric
mean titers were calculated from the individual titers of the cats from each group.
2.10. Data and Statistical Analyses
The analysis for the human part included data from 9 out of 10 participants and was performed
according to the "per protocol" (PP) analysis. Analyses were conducted in this way because one
participant had urticaria, accompanied by pruritus and wheal formation, on two occasions during
the study. The participant was unable to distinguish urticaria symptoms from the symptoms of cat
allergy and was thus excluded from analysis. The analyses of cat data included all 13 cats, whereas the
correlation of antibody responses in cats with measurements of human allergic symptoms included
data from 9 out of 10 participants with their respective study cats (n = 9).
Statistical analyses were performed with Excel, Graph Pad Prism and R. Data were summarized
by descriptive statistics: mean, standard deviation, median, first and third quartile, minimum, and
maximum. This study was classified as a pilot study because there was no pre-existing information
available concerning the expected change in symptoms of allergic cat owners before and after
immunization of their cats (the effect size). The changes in the symptoms of the main study were
evaluated using an exact Wilcoxon matched-paired signed rank test. Hypotheses were tested at a
two-sided significance level of α = 0.05. For comparison between baseline and course of study, the
mean of all values was computed.
3. Results
3.1. Study Design and Population
This trial was an open-label, non-placebo controlled, single-center, exploratory study involving
both cat-allergic humans and their cats (Figure 1). The aim of this methodology field trial was to assess
different tests to measure allergic symptoms and to monitor possible changes in allergic symptoms in
the study participants after their cats were immunized with the cat vaccine Fel-CuMV.
The study included 10 human participants (Table 1), ranging from 21 to 51 years old, and 13
cats (one participant had two cats and another three cats), ranging from 4 to 13 years old, of both
sexes and six different breeds. All ten participants who were screened were enrolled in the study.
There were no drop-outs and 10 of 10 participants completed the study. One participant suffered from
recurrent chronic urticaria of unknown origin, but exhibited no symptoms at the beginning of the
study. However, the urticaria occurred in study week 2 and again in week 16. On each occasion the
urticaria lasted for 4–5 weeks until recovery. The participant was not able to distinguish symptoms of
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urticaria from those of cat allergy and was excluded from the analysis. Data are thus presented as “per
protocol” (PP) analysis.
Figure 1. Study design of the combined human and animal trial. Prior to immunization of their cats,
participants performed a baseline assessment of their allergic symptoms using the HypoScore (OSSS
and petting time) and GWSS. In the course of the study, they performed the provocation test every
four weeks and recorded their general symptoms weekly without provocation using the GWSS. Cats
received three injections of 100 µg Fel-CuMV (HypoCatTM) at intervals of three weeks (in study weeks
4, 7 and 10) subcutaneously. Cat sera were collected at baseline, week 10, and week 27.
3.2. Adverse Events
Since there was no treatment of the participants, the risk of inducing study-related adverse events
was considered low. Nevertheless, some adverse events were recorded and included a cat bite during a
veterinary visit, chronic urticaria, erythema, common cold, and pruritus (Table 2). The participant bitten
by their cat during an immunization procedure at the veterinary practice was referred to their doctor
and received prophylactic antibiotic treatment. They fully recovered from the wound after 1 week.
Another participant #10 (excluded from analysis) suffered from an urticaria and presented with strong
pruritus and wheal formation. The symptoms were treated with topical urea, macrogol-6-laurylether
and fexofenadine-hydrochloride.
There were no severe adverse events observed in the cat population. Several minor clinical signs
were noted upon immunization with Fel-CuMV and were judged to be normal vaccination reactions
in cats. They disappeared within 72 h of administration. All reactions during and after injection of
Fel-CuMV were less frequent on the second and third dosing occasions. There were no treatment
related changes in body weight or temperature observed over the study period. Cat owners reported
no change in the behavior or appearance (e.g., fur condition) of the cats.
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Table 1. Study population.
Participant# Age Sex
Age When Allergy
Was Observed the
First Time
Affected Organs Baseline VAS Score
(0–10)
Without Direct
Interaction with Cat
Maximal VAS score
(0 –10)
After direct
interaction with cat
Continued in
Follow up
StudyEyes Nose Lungs/Bronchia Palate
1 50 female 10 x x 2.5 8.8 x
2 29 female 8 x x x 3.5 9.2 x
3 21 male 21 x x x 3.9 7.2 x
4 43 female 28 x x 1.1 7 x
5 24 female 22 x x x 3.7 7.2 x
6 45 male 23 x x 4.2 9 -
7 40 female 10 x x 1.3 5.6 x
8 28 female 12 x x 0.3 7.7 x
9 51 female 41 x x x 1.4 8.5 -
10 37 female 23 x x 1.9 4.9 -
Mean/Aver. 36.8 ±10.8 8 ♀; 2 ♂ 19.0 ± 11.3 9/10 7/10 6/10 2/10 2.4 ± 1.4 7.5 ± 1.4 7/10
Table 2. Adverse events.
Adverse Event Severity Participant # Total Number Percentage of All AEs Related to Intervention
Erythema and pruritus mild 9 3 17.6% Possible
Tooth infection moderate 9 1 5.9% No
Common cold mild 2, 4, 6, 8 6 35.2% No
Nausea with vomiting moderate 10 1 5.9% No
Nettle rash moderate 10 1 5.9% No
Cat allergy reactions mild 24 1 5.9% No
Swollen lips mild 10 1 5.9% No
Gastroenteritis moderate 8 1 5.9% No
Cat bite (hand) severe 2 1 5.9% Possible
Chronic urticaria (strong pruritus
and wheal formation) moderate 10 1 5.9% Possible
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3.3. Assessment of the OSSS after Provocation
Seven of nine participants showed lower OSSS at week 24 compared to baseline (Figure 2A)
demonstrating a change in the OSSS after provocation. The change from mean 11.7 at baseline to mean
7.3 at week 24 was not significant (p = 0.098). The change in the OSSS over the course of the study was
also assessed (Figure 2B–D). There was a significant reduction in the mean OSSS from week 8 to 24
(mean OSSS ranging from 6.4–9.1) compared to baseline (mean OSSS 11.7) (Figure 2B). The reduction
in the OSSS in seven of nine participants over the study period compared to baseline was statistically
significant (p = 0.03) (Figure 2C,D), demonstrating a sustained reduction in organ-specific symptoms
after vaccination of the cat observed from week 8 to week 24.
Figure 2. Organ specific symptom score (OSSS) after provocation. (A) Individual OSSS with SEM
of participants (n = 9) at baseline versus week 24 at the end of the study. (B) Mean OSSS with SEM
of participants (n = 9) at baseline and over the course of the study. (C) Individual mean OSSS with
SEM comparing baseline (weeks 1–3, n = 3) vs. treatment period (weeks 8, 12, 16, 20 and 24, n = 5).
(D) Individual mean OSSS (n = 9) with SEM comparing baseline (n = 3, weeks 1–3) vs. treatment
period (n = 5, weeks 8, 12, 16, 20 and 24). Statistical significances were obtained by an exact Wilcoxon
matched-paired signed rank test. Possible OSSS values from 0–30.
3.4. Petting Time
There were eight out of nine possible successes, meaning that the time of interaction with their
cats to reach a defined level of allergic symptoms for eight participants was greater at week 24 than the
mean baseline of weeks 1–3 (Figure 3A). The change from mean 16.9 min (1016 s) at baseline to mean
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27.7 min (1659 s) was statistically significant (p = 0.02). Of note, three participants had reached the
maximum interaction time of 45 min by the end of the study.
Figure 3. Time of petting as part of the provocation test. (A) Mean petting time with SEM in seconds of
nine participants comparing baseline (n = 3) versus week 24 at the end of the study. (B) Individual
mean petting time with SEM in seconds at baseline (n = 3, weeks 1–3) compared to treatment period
(n = 5, weeks 8, 12, 16, 20 and 24). (C) Factor of changed petting time for each participant shown as
ratio of the mean timepoints during treatment (n = 5, weeks 8, 12, 16, 20 and 24) to mean baseline time
(n = 3, weeks 1–3). (D) Change in % of the mean petting time with SEM of nine participants during the
treatment period in weeks 8, 12, 16, 20 and 24 compared to mean baseline in weeks 1–3. Statistical
significances were obtained by an exact Wilcoxon matched-paired signed rank test.
The improved petting time was apparent over the entire course of the study after vaccination of
the cats in weeks 4, 7 and 10 (Figure 3B–D). On a per participant basis, the petting time was increased in
seven of nine participants up to 6-fold (Figure 3B,C), which corresponded to an average improvement
of 100%–230% across weeks 8, 12, 16, 20, and 24 compared to baseline (Figure 3D).
3.5. General Weekly Symptom Score
There were eight of possible nine successes, meaning that the GWSS of eight participants were
lower at week 24 compared to baseline (Figure 4A). The mean GWSS at baseline compared to week 24
was significantly reduced from 7.2 to 4.4 (p = 0.023).
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Figure 4. General weekly symptom score GWSS. (A) Mean GWSS with SEM of participants (n = 9) at
baseline (n = 3, mean of weeks 1–3) versus week 24 at the end of the study. (B) Mean GWSS with SEM
of participants (n = 9) at baseline (n = 3, weeks 1–3) and over the course of the study (n = 22, weeks
4–25). (C) Individual mean GWSS with SEM at baseline (n = 3, weeks 1–3) compared to treatment
period (n = 22, weeks 4–25). (D) Mean GWSS with SEM of nine participants comparing baseline (n = 3,
weeks 1–3) vs. treatment period (n = 22, weeks 4–25). Statistical significances were obtained by an
exact Wilcoxon matched-paired signed rank test. Possible GWSS values from 0–30.
The average GWSS of all participants over the entire study period was also assessed (Figure 4B–D).
Towards the end of the study, the mean GWSS was consistently lower than the baseline values
(Figure 4B). Comparing the average baseline with the average treatment values of the GWSS, a change
in the general allergic symptoms (p = 0.039) was observed in eight of nine participants, demonstrating
a persistent improvement in symptoms upon immunization of the cats (Figure 4C,D).
3.6. Induction of Anti-Fel d 1 IgG Antibody Responses in Cats upon Vaccination with Fel-CuMV
Subcutaneous injection of Fel-CuMV vaccine was considered to be well-tolerated and safe, as only
mild and transient side reactions were noted. Cat sera were assessed for Fel d 1-specific IgG antibody
responses throughout the course of the study (Figure 5). Participant #8 had three cats, identified
as cats 8.1, 8.2, and 8.3. There are no serological data available for cat 8.3 because it rejected the
sampling procedure. There was a significant increase in anti-Fel d 1 IgG in all vaccinated cats (p < 0.001)
detectable after two immunizations at week 10. By the end of the study at week 27, the anti-Fel d
1-specific antibody response in sera (p = 0.001) was still significantly increased compared to baseline.
The antibody responses of the study cats were compared with the OSSS and petting time of the
provocation test and the GWSS of the participants at the corresponding timepoints (Figure 5C–E). The
parameters for assessing the allergic symptoms of the participants correlated well with the antibody
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responses in cats. Petting time showed a direct correlation with the anti-Fel d 1 IgG titers, whereas the
OSSS and the GWSS measurements were inversely correlated with the anti-Fel d 1 IgG titers.
Figure 5. Antibody responses in cat sera. (A) Anti-Fel d 1 IgG antibody titers in cats before and after
immunization, n = 12. (B) Mean anti-Fel d 1 IgG antibody titers with SEM, n = 12. (C) Anti-Fel d 1 IgG
antibody titers in cats at baseline (before immunization), week 10 and 27 vs. OSSS at corresponding
timepoints baseline (before immunization), week 8 and 24. (D) Anti-Fel d 1 IgG antibody titers in cats at
baseline (before immunization), week 10 and 27 vs. petting time at corresponding timepoints baseline
(before immunization), week 8 and 24. (E) Anti-Fel d 1 IgG antibody titers in cats at baseline (before
immunization), week 10 and 27 vs. GWSS at corresponding timepoints baseline (before immunization),
week 8 and 25. (C-E) Data included from participants (n = 9) with corresponding study cats (n = 9).
Statistical significances were obtained by an exact Wilcoxon matched-paired signed rank test.
3.7. Data of the Extension Study
After completion of the main study, an extension study was conducted with seven of the original
participants (Figure 6A). Reasons for the discontinuation of three participants were the exclusion of
the urticaria patient, the cat of one participant died due to a study-unrelated icterus, and personal
preferences of one participant.
The analysis presented in Figure 6 includes the data obtained from the seven participants and
their respective cats (seven study cats plus two cats; one participant had three cats), who participated
in both studies.
As described above, there was a reduction in the OSSS from week 8 to 24 (mean OSSS ranging from
4.3 to 5.6) compared to baseline (mean OSSS 12.3). The mean OSSS increased to 9.3 in the intervening
period between both studies (i.e., from week 24 to 54). After the boost immunization in week 56, there
was a small decrease in mean OSSS observed in study weeks 58 to 98 ranging from 6.0 to 7.4. Although
the reduction in the OSSS over both study periods compared to baseline was not statistically significant,
a trend of reduced OSSS was observed over the entire study period of almost 2 years (94 weeks) after
vaccination of the cats.
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Figure 6. Extension study: Changes in allergic symptoms of participants after booster injection of
cats. (A) Study design of the main and extension study including seven participants and nine cats.
In addition to the main study, the participants performed a provocation test before the boost (week
56) followed by four additional provocation tests in study weeks 58, 62, 78, and 98. Participants also
recorded their general organ specific symptoms (GSS) without provocation at monthly intervals during
the extension study. The cats received a boost immunization of 100 µg Fel-CuMV subcutaneously in
week 56. In addition to the collected serum samples of the main study, cat sera were also collected in
study weeks 56, 62, and 78. (B) Mean OSSS with SEM over the course of the main and extension study
of seven participants. (C) Mean petting time over the course of the main and extension study of seven
participants. (D) Mean general symptoms (G(W)SS) over the course of the main (assessed weekly) and
extension (assessed monthly) study of seven participants. (E) Measurement of anti-Fel d 1 IgG in cat
sera of nine cats participating in the main and extension study. (F) Mean anti-Fel d 1 IgG antibody titers
with SEM in cat sera. (G) Mean anti-Fel d 1 IgG antibody titers in cats vs. mean OSSS over the course
of the main (baseline (before immunization), week 8/10 and 24/27) and extension study (week 54/56
(before boost), week 62 and 78). (H) Mean anti-Fel d 1 IgG antibody titers in cats vs. mean petting time
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over the course of the main (baseline (before immunization), week 8/10 and 24/27) and extension
study (week 54/56 (before boost), week 62 and 78). (I) Mean anti-Fel d 1 IgG antibody titers in cats vs.
mean G(W)SS over the course of the main (baseline (before immunization), week 8/10 and 24/27) and
extension study (week 54/56 (before boost), week 62 and 78). (G-I) Data included from participants
(n = 7) with corresponding study cats (n = 7). Statistical significances were obtained by an exact
Wilcoxon matched-paired signed rank test.
The GSS followed a consistent trend of lower symptoms from week 5 to 25 after the initial cat
immunizations in weeks 4, 7 and 10 (Figure 6D). The mean GSS at baseline (weeks 1–3) of 7.5 improved
to a mean score of 6.8, which was already detectable in week 5, and further improved to 2.3 in study
week 14. By the end of the main study in week 25, the mean GSS of 4 was still lower compared to
baseline (i.e., GSS 7.5). Before cats received the boost injection in week 56, the mean GSS increased to
6.5 but was still lower compared to baseline (i.e., GSS 7.5 of weeks 1–3). Upon booster injection, allergic
symptoms improved again, reaching the lowest mean GSS of 3 in week 70. Clinical improvement was
still evident by the end of the study in week 98 (i.e., GSS 4.8). Notably, the participants had reduced
GSS at any timepoint after the first vaccination of their cats in study week 4, as the mean GSS over
both study periods was always lower compared to baseline (weeks 1–3).
Cat sera were assayed for Fel d 1-specific IgG antibodies throughout both study periods
(Figure 6E,F). The mean Fel d 1-specific IgG titers increased ~300-fold measured after two injections in
week 10 and were still on a high level at the end of the main study at week 27 (Figure 6F). Specific
antibodies declined between weeks 27 and 56 (before the boost) compared to the peak response detected
in week 10. Following administration of a booster injection in week 56, the specific IgG levels increased
again in eight of nine cats when measured by week 62, 6 weeks after the boost. Almost 4 months
later, by the end of the study in week 78, the anti-Fel d 1 IgG responses were still significantly higher
compared to baseline and were slightly above the antibody level measured before boost (week 56).
The antibody responses were inversely related to the OSSS and G(W)SS over the period of the
main and extension studies (Figure 6G,I). In contrast, antibody responses directly correlated to the
petting time of the provocation test (Figure 6H), indicating that specific antibodies reduced symptoms
and increased petting time. Specifically, after the induction of anti-Fel d 1 antibodies detected in week
10, the OSSS decreased from a mean score of 12.5 at baseline to 5.1 and 5.4, measured in week 8 and
24, respectively. During the intervening phase of the main and extension study, the antibody titers
declined and the mean OSSS increased to 9.3, detected in week 54. After the boost injection which
caused an increase in specific antibodies, the mean OSSS decreased to a mean score of 6.0 and 6.6 in
study weeks 62 and 78, respectively. Similar observations were made for G(W)SS.
The antibody titers also showed a correlation with petting time. Relative to baseline (week 1–3),
mean petting time and anti-Fel d 1 IgG, determined in week 8 and 10, increased the mean petting time
by a factor of 2, demonstrating that owners were found to be able to interact with their cats twice
as long before they developed an allergic symptom strength of 5 according to VAS. The subsequent
decrease in specific antibodies was associated with a decrease in petting time observed in weeks 24 and
54, although still above baseline. Upon the increase in specific antibodies after the booster injection,
petting time increased again by a factor of 2.3 compared to baseline.
4. Discussion
Allergy is the most common chronic disease in Europe and U.S and often manifests with chronic
conditions including rhinitis, conjunctivitis and asthma, which is associated with individual morbidity
and high socio-economic costs. In fact, more than 150 million Europeans are affected by chronic allergic
diseases (EAACI, 2016). The danger of developing chronic asthma is particularly high, especially
in allergies, which are caused by air-borne allergens such as hay fever and cat allergy. One in five
patients with allergies lives with the constant fear of getting an asthmatic or anaphylactic shock
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at any time or even dying as a result of a severe allergic reaction upon allergen encounter. The
World Health Organization estimates that approximately 300 million individuals currently suffer
from asthma worldwide and expect an increasing incidence to 400 million by 2025 [21,40]. This
development is worrisome, threatening health and economies alike, and demands action of the global
community for the development of new therapies, medications and diagnostic tools to address this
major challenge [7,41]. Cat allergy contributes to a significant proportion of the allergic disease burden.
There are several new therapeutic developments to treat cat allergy that are currently pursued
by various research groups and clinicians. Our novel approach of vaccinating the cat against Fel d 1,
offers a cost-effective therapy without the risk of inducing severe side effects in cat-allergic patients, as
they often occur during AITs, and without adversely affecting the cat. The vaccine targets Fel d 1, the
major cat allergen for humans. By immunizing cats, the reactive allergen level can be lowered, thereby
alleviating the symptoms of cat allergic patients. Here, we present clinical data of a first combined
human and animal field trial conducted as an open-label, exploratory methodological study. The aim
of the study was to assess different methods of measuring the allergic symptoms and determine if
those methods could detect changes in allergic symptoms after vaccination of cats with Fel-CuMV
(HypoCatTM).
The collection of clinical research data must be reproducible, valid and traceable using standardized
procedures [42,43]. However, the selection and combination of various tests and scoring systems for
monitoring allergic symptoms and their changes usually have a significant impact on the outcome of
clinical trials and the development of innovative medications. Therefore, it is advisable to select as few
questionnaires, tests and scoring systems as possible to capture the changes that best reflect the effect
of the treatment [44,45]. To this end, we developed a new method to record allergic symptoms by a
self-assessed, home-based symptom score, the provocation test. The validity of the test was evaluated
in a previously conducted human clinical trial involving non-immunized cats (NCT02399579). The
test consists of two elements: an assessment of organ-specific symptom score (OSSS) after petting—a
standardized score—and measurement of the time of petting the cat until a defined level of allergy
symptom was reached (level of 5 on a VAS). Both parameters, the OSSS and the time, are analyzed
separately. In addition to the provocation test, another self-assessed, home-based standard method
was investigated in this study: a general symptom score (G(W)SS) assessing the allergic symptoms
without provocation.
The mean OSSS as part of the provocation test at week 24 was reduced in seven of nine participants
compared to baseline. Moreover, the change in the OSSS was apparent throughout the course of the
main study (weeks 8, 12, 16, 20 and 24 vs. baseline) and showed a variable yet sustained reduction in
seven of nine participants. It should be noted that a reduction in the OSSS was not necessarily expected
to be large, since the cat owners were required to record their symptoms after petting the cat until they
had reached a symptom strength of 5 on the VAS. Hence, upon cessation of the provocation test (i.e.,
petting), the OSSS would have been similar on each occasion. A reason why a substantial decrease in
OSSS in the main study was achieved may have been due to the fact that three participants, at week 24,
were able to pet their cat for the maximum time of 45 min. In this circumstance, the VAS score of 5
was not reached, and thus the OSSS was lower. Regarding the extension study, several participants at
several occasions could pet their cat to the maximum petting time of 45 min and did not reach the
symptom strength of 5 on a VAS. Thus, the allergic symptoms were not as pronounced, resulting in
lower OSSS.
The second parameter of the provocation test was the petting time. Relative to baseline, an
increased time of petting was observed in eight of the nine participants at week 24 and over the
entire period of the main study in seven of the nine. The increase in petting time was even more
pronounced in the extension study. Several participants could pet their cat to the maximum time of 45
min on several occasions. The average petting time increased by a factor of two upon immunization
of the cats and showed a sustained improvement over the period of the main and extension studies,
demonstrating that the participants could interact longer with their cats.
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A change in general allergic symptoms without provocation assessed by the G(W)SS was noted
upon vaccination of the cats. Relative to baseline, a reduction in the GWSS at week 24 and over the
period of the main study was observed in eight of nine participants. Moreover, the GSS measured
throughout the course of the extension study showed a variable yet sustained reduction in seven of
seven participants. Of note, the improvement in general allergic symptoms of the participants recorded
without direct interaction with their cats at all timepoints after immunization of the cats over the period
of the main and extension studies indicates that the participants generally felt better and suffered less
from allergic symptoms.
Subcutaneous injection of three doses of Fel-CuMV vaccine followed by a single boost injection
a year later was considered to be well tolerated in several breeds of privately owned adult cats. No
serious adverse event occurred during the study. The clinical signs and reactions upon vaccination
with Fel-CuMV were mild and reversible. No related effects on body weight, food consumption,
behavior and appearance were observed. Moreover, the intended immunological response in cats
immunized with Fel-CuMV, i.e., induction of anti-Fel d 1 IgG antibodies, was achieved. Anti-Fel d 1
antibodies were measured in sera at week 10, three weeks after the second immunization. Previous
studies in cats (n > 60) with Fel-CuMV have shown that about 50% of immunized animals achieved
peak titers 2–3 weeks after the second immunization [36]. This would correspond to week 10 of the
current study. These findings support the observation of the improved symptoms assessed by the
provocation test and G(W)SS of the participants from week 8 and 6, respectively onwards, as Fel d
1-specific antibodies were present and had the potential to neutralize Fel d 1 as previously shown [36].
The improvement of symptoms had lessened by the end of the main study, which may be related
to the kinetics of the antibody response, which showed a decline from week 10 to week 27. Upon
administration of a booster injection, the symptoms and petting time improved again.
However, the results and conclusions of this open label, exploratory methodology study with a
small sample size (n = 9 in main and n = 7 in extension study) must be taken with caution. There was
no pre-existing information available regarding the expected change in symptoms of the participants
before and after immunization of their cats. As a consequence, no sample size calculation could
be done beforehand. Nevertheless, it is interesting to note that several parameters measured in the
study were suggestive that targeting the major cat allergen Fel d 1 by immunization of cats with
Fel-CuMV had a positive impact on the allergic sensation of the participant. In particular, the time that
participants were able to interact with their cats before a particular level of allergic symptoms was
reached increased significantly.
Improvements of the organ specific symptoms with (OSSS) and without provocation (G(W)SS)
over the course of the study were also noted. Notably, it was observed that the improvement in these
measures had lessened at the end of the main study but increased again after the booster injection.
This observation of the kinetics is valuable for planning and conducting further studies. Therefore,
all measured parameters (i.e., provocation test and GSS) are suitable to assess changes in allergic
symptoms of the cat owners.
Finally, from a veterinary perspective, targeting Fel d 1, the major cat allergen in humans, by active
vaccination has, to date, been well-tolerated. The general health status of the cats was not compromised
by the induction of auto-antibodies against Fel d 1. However, allergic symptoms of the cat allergic
owners were alleviated. As a result of the owner being less burdened by their allergy, the quality of
life of their cat may be improved. The ability of allergic cat owners to better tolerate and increase
the duration of their interactions with their pet can benefit the animal through better training and
socialization and awareness of the animals’ overall health. Moreover, the likelihood of abandonment
and subsequent euthanasia in animal shelters could be decreased.
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